Posted on 26/03/2025
In a major step toward redefining postoperative care and elevating patient experience, Rayner – a global leader in cataract surgery products – proudly announces the successful completion of its pivotal U.S. dropless cataract surgery study. OMIDRIA (phenylephrine and ketorolac intraocular solution 1% / 0.3%) is the only FDA-approved NSAID for use during cataract surgery, indicated
Posted on 3/02/2025
03.02.25 | Just 18 weeks on from the first implantation, Rayner is delighted to announce that it has now closed recruitment in the Investigational Device Exemption (IDE) study for the RayOne Galaxy intraocular lens in the USA. Developed in collaboration between Rayner, a global manufacturer of cataract surgery solutions, and ophthalmologist Dr João Lyra from
Posted on 23/01/2025
Mississauga, ON | 21 January 2025 Rayner, a global manufacturer of products for cataract surgery based in Worthing, UK, is pleased to announce the approval of RayOne EMV Toric (RAO210T) by Health Canada. Developed in collaboration with Professor Graham Barrett, RayOne EMV and RayOne EMV Toric are the only patented aspheric IOLs that induce controlled
Posted on 8/01/2025
Rayner, a global manufacturer of products for cataract surgery, today announces the launch of its redesigned online premium IOL calculator, RayTrace. One of the first online IOL calculation tools, RayTrace has been trusted by surgeons globally since 2008 for the accuracy of its premium IOL (toric, multifocal and supplementary) calculations, and has delivered over 360,000
Posted on 20/11/2024
Rayner, a global manufacturer of products for cataract surgery based in the United Kingdom, has launched a campaign to promote a dropless regimen with OMIDRIA® for postoperative cataract care. According to studies, up to 92% of patients struggle with self-administering postoperative eye drops. Inaccuracy with eye drops poses the risk of inconsistent or missed doses
Posted on 16/10/2024
Rayner, a global manufacturer of products for cataract surgery headquartered in Worthing, UK, announces the appointment of Scott Corning as Vice President, Americas. Scott comes to Rayner with 25 years of experience developing and driving successful brands and commercial teams within the ophthalmic pharmaceutical and medical device industries. Notably, Scott served as Senior Vice President,
Posted on 1/10/2024
Rayner, a global manufacturer of products for cataract surgery based in Worthing, UK, announces today that it has successfully implanted the first lenses in the RayOne Galaxy IOL U.S. Food and Drug Administration (FDA) approved Investigational Device Exemption (IDE) Study. The study is prospective, multicenter, randomised, masked and active controlled. If successful, the results of
Posted on 27/06/2024
Rayner, a global manufacturer of products for cataract surgery based in Worthing, UK, is delighted to announce that it has now closed recruitment in the Investigational Device Exemption (IDE) study for the EMV Toric Intraocular lens in the USA. The study reflects Rayner’s continued focus on optimising visual outcomes for surgeons and their patients and
Posted on 5/04/2024
Rayner, a global manufacturer of products for cataract surgery based in Worthing, UK, proudly announces delivery of its 5 millionth RayOne lens (and 11 millionth lens made from RayAcryl Rayner’s proprietary hydrophilic acrylic material), marking an important milestone in units sold globally. RayOne is Rayner’s fully-preloaded intraocular lens (IOL) injection system, providing smooth, consistent rolling
Posted on 25/03/2024
Rayner, a global manufacturer of products for cataract surgery headquartered in Worthing, UK, is proud to introduce their latest packaging, updated to reduce their carbon footprint, as a contribution to their environmental goals, and to improve ease of use for customers. The new packaging will include: Replacing traditional paper IFU documents with a QR code